Verrucarin J (Muconomycin B) is a metabolite of the Myrothecium fungus family. Verrucarin J generates reactive oxygen species (ROS) and induces apoptosis of cancer cell lines, such as A549, HCT 116 and SW-620 cells. Verrucarin J shows activities against Candida albicans and Mucor miehei. Verrucarin J inhibits arenavirus Junin (JUNV) yield with an IC50 of 1.2 ng/mL[2].In Vitro: Verrucarin J (0, 5, 10, 20, 50 nM; 24 hours) induces the apoptosis of A549 cells.
Verrucarin J (0, 1, 2, 5, 10, 20, 50 nM; 24, 48, 72 hours) significantly inhibits cell proliferation of A549 and H1793 cells with IC50 values of approximately 10 nM and 20 nM after 48 h of treatment, respectively.
Verrucarin J (0, 0.1, 0.2, 0.3, 0.4, 0.5 μM; 24 hours) has an IC50 of 300 nM for HCT 116 and SW-620 cell proliferation[2].
Verrucarin J (0, 10, 20 nM, 48 hours) inhibits cancer stem cell (CSC) self-renewal pathways Wnt1/β-catenin and Notch1 and down-regulates the expression of key CSC specific genes (ALDH1, LGR5, OCT4 and CD133) of A549 cells.
Verrucarin J (compound 2; 50 μg/disk) shows noteworthy activities against Candida albicans and Mucor miehei.
Verrucarin J reduces JUNV yield more than 2 log units and has a similar effect against the arenavirus Tacaribe.
Verrucarin J reduces the cell viability of Vero cells with a cytotoxic concentration 50% (CC50) of 8.2 ng/mL.
In Vivo: Verrucarin J (0.5?mg/kg; i.p. for 4 weeks) suppresses AKT-induced tumor growth in a xenograft model[2].
Verrucarin J (0.1, 0.5, 2.0 mg/kg; i.p. for three weeks) is a highly potent anticancer drug and suppresses tumor growth and metastasis.